Skip to main content

Institutional intelligence for APOLLO HOSPITALS ENTERPRISE LT

Cross-view mutual fund activity and super-investor shareholding · Jun 2026 SHP.

Ownership breakdown

Category totals from the official quarterly Shareholding Pattern filing (Jun 2026). Sums to 100.00%.

  • Promoters28.02%
  • FII41.50%
  • Mutual Funds17.33%
  • DII (ex-MF)6.39%
  • Retail & others6.76%
  • 1% Club 8.86%(subset)

Super Investors and 1% Club names below are disclosed holders at or above 1%. They are subsets of the categories above, not additive. View filing

Holder details (≥1% disclosed names)

FII / FPI

Foreign portfolio investors

41.50%4 named
HolderStakeSharesValue (₹ Cr)
1.64%23,61,960
1.39%19,92,112
1.10%15,81,082
1.05%15,09,918

Promoters

Promoter & promoter group

28.02%5 named
HolderStakeSharesValue (₹ Cr)
18.93%2,72,23,124
2.04%29,37,066
1.69%24,32,508
1.56%22,39,952
1.10%15,77,350

1% Club — Individuals & others

Non-promoter ≥1% holders not matched to a curated profile

8.86%6 named
HolderStakeSharesValue (₹ Cr)
2.32%33,33,586
1.50%21,57,205
1.39%19,93,863
1.31%18,77,338
1.19%17,05,664
1.15%16,54,510

Mutual Funds

Domestic mutual funds & UTI

17.33%1 named
HolderStakeSharesValue (₹ Cr)
1.79%25,78,658

DII (other)

Insurance, banks, AIF, other domestic institutions

6.39%1 named
HolderStakeSharesValue (₹ Cr)
Tracked as LIC1.97%28,30,488

Retail & others

Holders below 1% disclosure threshold and public non-institutions

6.76%

SEBI requires naming only shareholders with ≥1% stake. The remaining 6.76% includes retail investors, small HNIs, employee trusts, and other holders below the disclosure threshold — aggregated in the official filing.

Super Investors

Curated tracked investor profiles

No names

No curated super investor holds ≥1% in the latest filing. See FII, DII, and mutual fund holders in the sections above.

Shareholding data sourced from NSE/BSE regulatory filings. Category chart uses official filing totals; named holder lists include every disclosed ≥1% position. Not investment advice. See our disclaimer and methodology.